Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Trial Details

NCT ID

NCT07214779

Phase

PHASE3

Sponsor

Incyte Corporation

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• INCB123667
• Investigator's choice of chemotherapy

Locations (sample)

• Anchorage, Alaska, United States|61.21806,-149.90028
• Tucson, Arizona, United States|32.22174,-110.92648
• Duarte, California, United States|34.13945,-117.97729
• Los Angeles, California, United States|34.05223,-118.24368
• Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

• Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Have platinum-resistant disease.
• Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum containing regimen.
• Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.